ClinicalTrials.gg
CompletedNCT07058922Updated Nov 13, 2026

Acute Effects of Powdered Beetroot Extract Supplementation on the Microcirculation of Resistant Hypertensive Individuals

A Phase 1 interventional study of evaluation of systemic microvascular reactivity and ABPM in Resistant Arterial Hypertension, sponsored by National Institute of Cardiology, Laranjeiras, Brazil. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by National Institute of Cardiology, Laranjeiras, Brazil · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2024, registered Jul 2025).
Updated Nov 13, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Enrollment
81st of 189
100 · median 80
Started
2024
with 11 others
Phase 1
2 of 209
1 open now
Registered
194th of 209
by date
Lead sponsor
5 of 209
National Institute of Cardiology, Laranjeiras, Brazil

Among the 209 studies in Hypertension with a site in Brazil, this one is the 81st largest by enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 2 in phase 1, and was the 194th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

Arterial hypertension is a major public health issue and is considered to be a new epidemic due to its high mortality and morbidity rates. Elevated blood pressure levels increase the risk of coronary artery disease, heart failure, stroke, chronic kidney disease and death. Dietary nitrate supplementation in the form of beetroot powder extract may offer a more accessible way to increase systemic nitric oxide availability and consequently promote vasodilation in these patients. However, studies are needed to assess its benefits in patients with hypertension.

Read the detailed description

Methods and Analyses: This is a double-blind, placebo-controlled clinical trial in which patients with hypertension will be randomly assigned to two groups to receive either nitrate powder supplementation or placebo for a duration of 60 days. The primary outcome will be the reduction in blood pressure levels. Secondary outcomes will include systemic microvascular reactivity and quality of life.

03

Conditions studied

  • Resistant Arterial Hypertension

Browse trials for

Keywords

  • arterial hypertension
  • systemic microcirculation
  • beetroot extract
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resistant hypertensive patients, with a diagnosis documented in medical records, without any change in medication or increase in dosage in the past 30 days.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from the study if they have: neoplasms, heart failure, are using medications containing nitrate in their formulation, or have undergone renal denervation.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    beetroot powder extract supplement

    A powdered beetroot extract supplement containing 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.

    Diagnostic Test: evaluation of systemic microvascular reactivity · Diagnostic Test: ABPM · Dietary Supplement: beetroot supplement

  • Placebo comparator
    placebo control

    An isocaloric, colored, and flavored supplement composed of maltodextrin will be orally administered.

    Diagnostic Test: evaluation of systemic microvascular reactivity · Diagnostic Test: ABPM

Interventions

  • Diagnostic testevaluation of systemic microvascular reactivity

    Evaluation of systemic microvascular reactivity using laser speckle contrast imaging.

  • Diagnostic testABPM

    Ambulatory blood pressure measuring: systolic, diastolic and mean arterial pressures

  • Dietary supplementbeetroot supplement

    A powdered beetroot extract supplement containing 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.

06

What researchers measure

Primary outcomes

  1. Blood pressure

    ABPM - measurement of systolic, diastolic and mean arterial pressure.

    Time frame: 60 days of tratment

Secondary outcomes

  1. Systemic microvascular reactivity

    Time frame: 60 days treatment

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2026, 29 months.

Of 44 non-industry phase 1 interventional studies under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's 29 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2026 → Nov 2026 and completion Dec 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 10, 2025
StartActual
Jun 1, 2024
Primary completionActual
Nov 9, 2026was Dec 2026
CompletionActual
Nov 9, 2026was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 13, 2026
Primary completion
Dec 2026→Nov 9, 2026 (actual)
Nov 13, 2026
Study completion
Dec 2026→Nov 9, 2026 (actual)
Nov 13, 2026
Design
Early Phase 1→Phase 1
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Enrolling by invitation→Completed
    Primary completion Dec 2026→Nov 9, 2026 (now actual)
    Study completion Dec 2026→Nov 9, 2026 (now actual)
    Design Early Phase 1→Phase 1
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07058922
Lead sponsor
National Institute of Cardiology, Laranjeiras, Brazil
Responsible party
Eduardo Tibirica, MD, PhD (senior researcher, National Institute of Cardiology, Laranjeiras, Brazil) — Principal investigator
First posted
Jul 10, 2025
Start date
Jun 1, 2024
Primary completion
Nov 9, 2026
Completion
Nov 9, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion